Panzytrat 20,000 U produced by Knoll is a modern galenic form of active pancreatic
enzymes in the form of microgranules with uniform enzymatic composition. The studies of the preparation effectiveness were carried out in 88 patients with diagnosed exocrine failure in the course of
chronic pancreatitis. The patients were taking
Panzytrat 20,000 for 4 weeks in doses 3 x 1
capsule with main meals. Control examinations were performed two and four weeks after starting the treatment, assessing the patients' condition on the basis of history taking and medical examination; taking into account
weight gain, duration and intensity of
pain and dyspeptic symptoms, frequency and character of defeacations and possible undesirable effects. In a group of 37 patients, BNT-
PABA test was also performed before the treatment and after one
capsule of
Panzytrat. The treatment with
Panzytrat 20,000 caused a statistically significant reduction of the number of defecations, significant reduction of
pain and dyspeptic symptoms. A statistically significant increase of
PABA recovery in urine was also obtained after one
capsule of the preparation. Practically, no unfavourable effects of the treatment were observed. The studies carried out point to the high effectiveness of
Panzytrat in dose 3 x 20,000. U daily in the treatment of exocrine pancreatic failure in the course of
chronic pancreatitis.